This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424. doi: 10.3322/caac.21492BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalAGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin20186839442410.3322/caac.21492Open DOISearch in Google Scholar
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-53. doi: 10.1002/ijc.31937FerlayJColombetMSoerjomataramIMathersCParkinDMPiñerosMet alEstimating the global cancer incidence and mortality in 2018 GLOBOCAN sources and methodsInt J Cancer201914419415310.1002/ijc.31937Open DOISearch in Google Scholar
Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-44. doi: 10.1200/JCO.2005.04.4859GovindanRPageNMorgenszternDReadWTierneyRVlahiotisAet alChanging epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results databaseJ Clin Oncol20062445394410.1200/JCO.2005.04.4859Open DOISearch in Google Scholar
Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, Møller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 2012; 75: 280-4. doi: 10.1016/j.lungcan.2011.08.004RiazSPLüchtenborgMCouplandVHSpicerJPeakeMDMøllerHTrends in incidence of small cell lung cancer and all lung cancerLung Cancer201275280410.1016/j.lungcan.2011.08.004Open DOISearch in Google Scholar
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8: 1563-74. doi: 10.1200/JCO.1990.8.9.1563AlbainKSCrowleyJJLeBlancMLivingstonRBDeterminants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data baseJ Clin Oncol1990815637410.1200/JCO.1990.8.9.1563Open DOISearch in Google Scholar
Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007; 12: 1096-104. doi: 10.1634/theoncologist.12-9-1096LallyBEUrbanicJJBlackstockAWMillerAAPerryMCSmall cell lung cancer: have we made any progress over the last 25 years?Oncologist200712109610410.1634/theoncologist.12-9-1096Open DOISearch in Google Scholar
Yang Y, Yuan G, Zhan C, Huang Y, Zhao M, Yang X, et al. Benefits of surgery in the multimodality treatment of stage IIB-IIIC small cell lung cancer. J Cancer 2019; 10: 5404-12. doi: 10.7150/jca.31202YangYYuanGZhanCHuangYZhaoMYangXet alBenefits of surgery in the multimodality treatment of stage IIB-IIIC small cell lung cancerJ Cancer20191054041210.7150/jca.31202Open DOISearch in Google Scholar
Lassen U, Østerlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J Clin Oncol 1995; 13: 1215-20. doi: 10.1200/JCO.1995.13.5.1215LassenUØsterlindKHansenMDombernowskyPBergmanBHansenHHLong-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patientsJ Clin Oncol19951312152010.1200/JCO.1995.13.5.1215Open DOISearch in Google Scholar
Kato Y, Ferguson TB, Bennett DE, Burford TH. Oat cell carcinoma of the lung. A review of 138 cases. Cancer 1969; 23: 517-24. 10.1002/1097-0142(196903)23:3<517::aid-cncr2820230301>3.0.co;2-lKatoYFergusonTBBennettDEBurfordTHOat cell carcinoma of the lung. A review of 138 casesCancer1969235172410.1002/1097-0142(196903)23:3<517::aid-cncr2820230301>3.0.co;2-lOpen DOISearch in Google Scholar
Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017; 18: 1116-25. doi: 10.1016/S1470-2045(17)30318-2Faivre-FinnCSneeMAshcroftLAppelWBarlesiFBhatnagarAet alConcurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trialLancet Oncol20171811162510.1016/S1470-2045(17)30318-2Open DOISearch in Google Scholar
Simone CB 2nd, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, et al. Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline. Pract Radiat Oncol 2020; 10: 158-73. doi: 10.1016/j.prro.2020.02.009SimoneCBBogartJACabreraARDalyMEDeNunzioNJDetterbeckFet alRadiation therapy for small cell lung cancer: an ASTRO clinical practice guidelinePract Radiat Oncol2020101587310.1016/j.prro.2020.02.009Open DOISearch in Google Scholar
Stanic K, Vrankar M, But-Hadzic J. Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy. Radiol Oncol 2020; 29; 54: 353-63. doi: 10.2478/raon-2020-0046StanicKVrankarMBut-HadzicJConsolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapyRadiol Oncol202029543536310.2478/raon-2020-0046Open DOISearch in Google Scholar
Tian S, Zhang X, Jiang R, Pillai RN, Owonikoko TK, Steuer CE, et al. Survival outcomes with thoracic radiotherapy in extensive-stage small-cell lung cancer: a propensity score-matched analysis of the national cancer database. Clin Lung Cancer 2019; 20: 484-93.e6. doi: 10.1016/j.cllc.2019.06.014TianSZhangXJiangRPillaiRNOwonikokoTKSteuerCEet alSurvival outcomes with thoracic radiotherapy in extensive-stage small-cell lung cancer: a propensity score-matched analysis of the national cancer databaseClin Lung Cancer2019204849310.1016/j.cllc.2019.06.014Open DOISearch in Google Scholar
Tay RY, Heigener D, Reck M, Califano R. Immune checkpoint blockade in small cell lung cancer. Lung Cancer 2019; 137: 31-7. doi: 10.1016/j.lungcan.2019.08.024TayRYHeigenerDReckMCalifanoRImmune checkpoint blockade in small cell lung cancerLung Cancer201913731710.1016/j.lungcan.2019.08.024Open DOISearch in Google Scholar
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379: 2220-9. doi: 10.1056/NEJMoa1809064HornLMansfieldASSzczęsnaAHavelLKrzakowskiMHochmairMJet alFirst-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancerN Engl J Med20183792220910.1056/NEJMoa1809064Open DOISearch in Google Scholar
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394: 1929-39. doi: 10.1016/S0140-6736(19)32222-6Paz-AresLDvorkinMChenYReinmuthNHottaKTrukhinDet alDurvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialLancet201939419293910.1016/S0140-6736(19)32222-6Open DOISearch in Google Scholar
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44. doi: 10.1038/nature07205MantovaniAAllavenaPSicaABalkwillFCancer-related inflammationNature20084544364410.1038/nature0720518650914Open DOISearch in Google Scholar
Tan CSY, Read JA, Phan VH, Beale PJ, Peat JK, Clarke SJ. The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. Support Care Cancer 2015; 23: 385-91. doi: 10.1007/s00520-014-2385-yTanCSYReadJAPhanVHBealePJPeatJKClarkeSJThe relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort studySupport Care Cancer2015233859110.1007/s00520-014-2385-y25112562Open DOISearch in Google Scholar
Zheng J, Seier K, Gonen M, Balachandran V, Kingham T, D’Angelica M, et al. Utility of serum inflammatory markers for predicting microvascular invasion and survival for patients with hepatocellular carcinoma. Ann Surg Oncol 2017; 24: 3706-14. doi: 10.1245/s10434-017-6060-7ZhengJSeierKGonenMBalachandranVKinghamTD’AngelicaMet alUtility of serum inflammatory markers for predicting microvascular invasion and survival for patients with hepatocellular carcinomaAnn Surg Oncol20172437061410.1245/s10434-017-6060-7845743628840521Open DOISearch in Google Scholar
Maestu I, Pastor M, Gómez-Codina J, Aparicio J, Oltra A, Herranz C, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997; 8: 547-53. doi: 10.1023/a:1008212826956MaestuIPastorMGómez-CodinaJAparicioJOltraAHerranzCet alPretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patientsAnn Oncol199785475310.1023/a:1008212826956Open DOISearch in Google Scholar
Alexandrakis M, Passam F, Moschandrea I, Christophoridou A, Pappa C, Coulocheri S, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26: 135-40. doi: 10.1097/00000421-200304000-00007AlexandrakisMPassamFMoschandreaIChristophoridouAPappaCCoulocheriSet alLevels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosisAm J Clin Oncol2003261354010.1097/00000421-200304000-00007Open DOISearch in Google Scholar
Petekkaya I, Unlu O, Roach E, Gecmez G, Okoh A, Babacan T, et al. Prognostic role of inflammatory biomarkers in metastatic breast cancer. J BUON 2017; 22: 614-22.PetekkayaIUnluORoachEGecmezGOkohABabacanTet alPrognostic role of inflammatory biomarkers in metastatic breast cancerJ BUON20172261422Search in Google Scholar
Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003; 39: 303-13. doi: 10.1016/s0169-5002(02)00508-1BremnesRMSundstromSAasebøUKaasaSHatlevollRAamdalSThe value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-upLung Cancer2003393031310.1016/s0169-5002(02)00508-1Open DOISearch in Google Scholar
Haas M, Heinemann V, Kullmann F, Laubender R, Klose C, Bruns C, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 2013; 139: 681-9. doi: 10.1007/s00432-012-1371-3HaasMHeinemannVKullmannFLaubenderRKloseCBrunsCet alPrognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapyJ Cancer Res Clin Oncol2013139681910.1007/s00432-012-1371-323315099Open DOISearch in Google Scholar
Bernhardt D, Aufderstrasse S, König L, Adeberg S, Bozorgmehr F, Christopoulos P, et al. Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy. Cancer Manag Res 2018; 10: 6563-9. doi: 10.2147/CMAR.S180990BernhardtDAufderstrasseSKönigLAdebergSBozorgmehrFChristopoulosPet alImpact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapyCancer Manag Res2018106563910.2147/CMAR.S180990628089030555261Open DOISearch in Google Scholar
Oh SY, Heo J, Noh OK, Chun M, Cho O, Oh YT. Absolute lymphocyte count in preoperative chemoradiotherapy for rectal cancer: changes over time and prognostic significance. Technol Cancer Res Treat 2018; 17: 1533033818780065. doi: 10.1177/1533033818780065OhSYHeoJNohOKChunMChoOOhYTAbsolute lymphocyte count in preoperative chemoradiotherapy for rectal cancer: changes over time and prognostic significanceTechnol Cancer Res Treat201817153303381878006510.1177/1533033818780065602426929909729Open DOISearch in Google Scholar
Ozmen S, Timur O, Calik I, Altinkaynak K, Simsek E, Gozcu H, et al. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer. Endocr Regul 2017; 51: 131-6. doi: 10.1515/enr-2017-0013OzmenSTimurOCalikIAltinkaynakKSimsekEGozcuHet alNeutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancerEndocr Regul201751131610.1515/enr-2017-001328858848Open DOISearch in Google Scholar
Acartürk Tunçay E, Karakurt Z, Aksoy E, Saltürk C, Gungor S, Ciftaslan N, et al. Eosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation marker. Int J Chron Obstruct Pulmon Dis 2017; 12: 3361-70. doi: 10.2147/COPD.S147261AcartürkTunçay EKarakurtZAksoyESaltürkCGungorSCiftaslanNet alEosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation markerInt J Chron Obstruct Pulmon Dis20171233617010.2147/COPD.S147261570316129200843Open DOISearch in Google Scholar
Zhao Q, Yang Y, Xu S, Zhang X, Wang H, Zhang H, et al. Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients. Onco Targets Ther 2015; 8: 2731-8. doi: 10.2147/OTT.S90875ZhaoQYangYXuSZhangXWangHZhangHet alPrognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patientsOnco Targets Ther201582731810.2147/OTT.S90875459907126491346Open DOISearch in Google Scholar
Yu Y, Qian L, Cui J. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patients. Mol Clin Oncol 2017; 7: 498-506. doi: 10.3892/mco.2017.1342YuYQianLCuiJValue of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patientsMol Clin Oncol2017749850610.3892/mco.2017.1342554776628811903Open DOISearch in Google Scholar
Zhao QT, Yuan Z, Zhang H, Zhang X, Wang H, Wang Z, et al. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3,720 patients. Int J Cancer 2016; 139: 164-70. doi: 10.1002/ijc.30060ZhaoQTYuanZZhangHZhangXWangHWangZet alPrognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3,720 patientsInt J Cancer20161391647010.1002/ijc.3006026915723Open DOISearch in Google Scholar
Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.OkenMCreechRTormeyDHortonJDavisTMcFaddenEet alToxicity and response criteria of the Eastern Cooperative Oncology GroupAm J Clin Oncol198256495510.1097/00000421-198212000-00014Search in Google Scholar
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi99-vi105. doi: 10.1093/annonc/mdt178FrühMDeRuysscher DPopatSCrinòLPetersSFelipESmall-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 6: vi99-vi10510.1093/annonc/mdt17823813929Open DOISearch in Google Scholar
Sakin A, Sahin S, Yasar N, Demir C, Arici S, Geredeli C, et al. The relation between hemogram parameters and survival in extensive-stage small cell lung cancer. Oncol Res Treat 2019; 42: 506-15. doi: 10.1159/000501595SakinASahinSYasarNDemirCAriciSGeredeliCet alThe relation between hemogram parameters and survival in extensive-stage small cell lung cancerOncol Res Treat2019425061510.1159/00050159531336378Open DOISearch in Google Scholar
Käsmann L, Bolm L, Schild SE, Janssen S, Rades D. Neutrophil-to-lymphocyte ratio predicts outcome in limited disease small-cell lung cancer. Lung 2017; 195: 217-24. doi: 10.1007/s00408-017-9976-6KäsmannLBolmLSchildSEJanssenSRadesDNeutrophil-to-lymphocyte ratio predicts outcome in limited disease small-cell lung cancerLung20171952172410.1007/s00408-017-9976-628154994Open DOISearch in Google Scholar
Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 2014; 111: 452-60. doi: 10.1038/bjc.2014.317KangMHGoSISongHNLeeAKimSHKangJHet alThe prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancerBr J Cancer20141114526010.1038/bjc.2014.317411998624921916Open DOISearch in Google Scholar
Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 2015; 236: 297-304. doi: 10.1620/tjem.236.297HongXCuiBWangMYangZWangLXuQSystemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancerTohoku J Exp Med201523629730410.1620/tjem.236.29726250537Open DOISearch in Google Scholar
Go SI, Kim RB, Song HN, Kang MH, Lee US, Choi HJ. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. Med Oncol 2014; 31: 323. doi: 10.1007/s12032-014-0323-yGoSIKimRBSongHNKangMHLeeUSChoiHJPrognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancerMed Oncol20143132310.1007/s12032-014-0323-y25417187Open DOISearch in Google Scholar
Proctor MJ, Morrison DS, Talwar D, Balmer S, Fletcher C, O’reilly D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47: 2633-41. doi: 10.1016/j.ejca.2011.03.028ProctorMJMorrisonDSTalwarDBalmerSFletcherCO’reillyDet alA comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome StudyEur J Cancer20114726334110.1016/j.ejca.2011.03.02821724383Open DOISearch in Google Scholar
Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990; 61: 597-604. doi: 10.1038/bjc.1990.133RawsonNSPetoJAn overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer ResearchBr J Cancer19906159760410.1038/bjc.1990.13319713812158808Open DOISearch in Google Scholar
Cao S, Jin S, Shen J, Cao J, Zhang H, Meng Q, et al. Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients. Oncotarget 2017; 8: 8657-69. doi: 10.18632/oncotarget.14395CaoSJinSShenJCaoJZhangHMengQet alSelected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patientsOncotarget2017886576910.18632/oncotarget.14395535243028055965Open DOISearch in Google Scholar
Lohinai Z, Bonanno L, Aksarin A, Pavan A, Megyesfalvi Z, Santa B, et al. Neutrophil–lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. Peer J 2019; 7: e7232. doi: 10.7717/peerj.7232LohinaiZBonannoLAksarinAPavanAMegyesfalviZSantaBet alNeutrophil–lymphocyte ratio is prognostic in early stage resected small-cell lung cancerPeer J20197e723210.7717/peerj.7232667342631392087Open DOISearch in Google Scholar
Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, et al. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol 2018; 126: 499-505. doi: 10.1016/j.radonc.2017.12.030SuzukiRLinSHWeiXAllenPKWelshJWByersLAet alPrognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancerRadiother Oncol201812649950510.1016/j.radonc.2017.12.030585662029398150Open DOISearch in Google Scholar
Pan Z, Zhang L, Liu C, Huang X, Shen S, Lin X, et al. Cisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selection. Oncol Lett 2019; 18: 1513-20. doi: 10.3892/ol.2019.10459PanZZhangLLiuCHuangXShenSLinXet alCisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selectionOncol Lett20191815132010.3892/ol.2019.10459660739631423218Open DOISearch in Google Scholar
Zheng Y, Wang L, Zhao W, Dou Y, Lv W, Yang H, et al. Risk factors for brain metastasis in patients with small cell lung cancer without prophylactic cranial irradiation. Strahlenther Onkol 2018; 194: 1152-62. doi: 10.1007/s00066-018-1362-7ZhengYWangLZhaoWDouYLvWYangHet alRisk factors for brain metastasis in patients with small cell lung cancer without prophylactic cranial irradiationStrahlenther Onkol201819411526210.1007/s00066-018-1362-730218136Open DOISearch in Google Scholar
Wen Q, Meng X, Xie P, Wang S, Sun X, Yu J. Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy. Oncotarget 2017; 8: 81405-18. doi: 10.18632/oncotarget.19073WenQMengXXiePWangSSunXYuJEvaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapyOncotarget20178814051810.18632/oncotarget.19073565529529113400Open DOISearch in Google Scholar
Xie D, Marks R, Zhang M, Jiang G, Jatoi A, Garces YI, et al. Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. J Thorac Oncol 2015; 10: 1213-20. doi: 10.1097/JTO.0000000000000585XieDMarksRZhangMJiangGJatoiAGarcesYIet alNomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markersJ Thorac Oncol20151012132010.1097/JTO.000000000000058526200277Open DOISearch in Google Scholar
Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH. Prognostic significance of total lymphocyte count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in limited-stage small-cell lung cancer. Clin Lung Cancer 2019; 20: 117-23. doi: 10.1016/j.cllc.2018.11.013SuzukiRWeiXAllenPKCoxJDKomakiRLinSHPrognostic significance of total lymphocyte count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in limited-stage small-cell lung cancerClin Lung Cancer2019201172310.1016/j.cllc.2018.11.01330611672Open DOISearch in Google Scholar
Pan H, Shi X, Xiao D, He J, Zhang Y, Liang W, et al. Nomogram prediction for the survival of the patients with small cell lung cancer. J Thorac Dis 2017; 9: 507-18. doi: 10.21037/jtd.2017.03.121PanHShiXXiaoDHeJZhangYLiangWet alNomogram prediction for the survival of the patients with small cell lung cancerJ Thorac Dis201795071810.21037/jtd.2017.03.121539404828449457Open DOISearch in Google Scholar
Zhang Q, Qu Y, Liu H, Jia H, Wen F, Pei S, et al. Initial platelet-to-lymphocyte count as prognostic factor in limited-stage small cell lung cancer. Biomark Med 2019; 13: 249-58. doi: 10.2217/bmm-2018-0415ZhangQQuYLiuHJiaHWenFPeiSet alInitial platelet-to-lymphocyte count as prognostic factor in limited-stage small cell lung cancerBiomark Med2019132495810.2217/bmm-2018-041530624082Open DOISearch in Google Scholar
Liu D, Huang Y, Li L, Song J, Zhang L, Li W. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer. BMC Cancer 2017; 17: 882. doi: 10.1186/s12885-017-3893-1LiuDHuangYLiLSongJZhangLLiWHigh neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancerBMC Cancer20171788210.1186/s12885-017-3893-1574093329268698Open DOISearch in Google Scholar
Wang X, Teng F, Kong L, Yu J. Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. Onco Targets Ther 2016; 9: 5761-70. doi: 10.2147/OTT.S106296WangXTengFKongLYuJPretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancerOnco Targets Ther2016957617010.2147/OTT.S106296503659327703374Open DOISearch in Google Scholar
Mirili C, Guney IB, Paydas S, Seydaoglu G, Kapukaya TK, Ogul A, et al. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC). Int J Clin Oncol 2019; 24: 168-78. doi: 10.1007/s10147-018-1338-8MiriliCGuneyIBPaydasSSeydaogluGKapukayaTKOgulAet alPrognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC)Int J Clin Oncol2019241687810.1007/s10147-018-1338-830109543Open DOISearch in Google Scholar
Deng M, Ma X, Liang X, Zhu C, Wang M. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget 2017; 8: 37200-7. doi: 10.18632/oncotarget.16553DengMMaXLiangXZhuCWangMAre pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?Oncotarget2017837200710.18632/oncotarget.16553551490228380461Open DOISearch in Google Scholar
Yin X, Yan D, Qiu M, Huang L, Yan SX. Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis. BMC Cancer 2019; 19: 95. doi: 10.1186/s12885-018-5251-3YinXYanDQiuMHuangLYanSXProphylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysisBMC Cancer2019199510.1186/s12885-018-5251-3634161530665432Open DOISearch in Google Scholar
